Application of highly sensitive UPLC–MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [18F]FPWAY
Authors:
- Ying MaYing Ma
- Lixin LangLLLixin Lang
- Larry ReyesLRLarry Reyes
- Joji TokugawaJTJoji Tokugawa
- Elaine M. JagodaEJElaine M. Jagoda
- Dale O. KiesewetterDKDale O. Kiesewetter
- 1 May 2009
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (4) , 389-393
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Species differences in metabolites of PET ligands: serotonergic 5-HT1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAYNuclear Medicine and Biology, 2006
- Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studiesNuclear Medicine and Biology, 2006
- Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635Bioorganic & Medicinal Chemistry, 2006
- Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracerLife Sciences, 2006
- Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: Dopamine D2, serotonin 2A and NK-1 receptors as examplesLife Sciences, 2005
- Application of LC-MS to the analysis of new radiopharmaceuticalsMolecular Imaging and Biology, 2003
- Fluoro analogs of WAY-100635 with varying pharmacokinetics propertiesNuclear Medicine and Biology, 2000
- Development of Fluorine-18-Labeled 5-HT1AAntagonistsJournal of Medicinal Chemistry, 1999
- First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635European Journal of Pharmacology, 1995
- [11C]WAY 100635: A radioligand for imaging 5-HT1A receptors with positron emission tomographyLife Sciences, 1994